NCT01287182View on ClinicalTrials.gov

Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Atherosclerosis
Interventions
DRUG

Ateronon

Ateronon daily for 3 months

Trial Locations (1)

Unknown

Rafic Hariri University Hospital, Beirut

Sponsors
All Listed Sponsors
lead

Omicron Pharmaceuticals

INDUSTRY

NCT01287182 - Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis | Biotech Hunter | Biotech Hunter